International Journal of COPD

Publisher: Dove Medical Press

Journal description

An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals.

Current impact factor: 2.73

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.732

Additional details

5-year impact 0.00
Cited half-life 0.00
Immediacy index 0.00
Eigenfactor 0.00
Article influence 0.00
Website International Journal of COPD website
Other titles International journal of chronic obstructive pulmonary disease (Online), Int J Chron Obstruct Pulmon Dis (Online), International journal of COPD (Online)
ISSN 1176-9106
OCLC 243780689
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Dove Medical Press

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • On institutional repository, central repository or subject -based repository, including PubMed Central
    • Creative Commons Attribution Non-Commercial License
    • UK funded authors may use a Creative Commons Attribution License
    • On a non-profit server
    • Must link to publisher version
    • Published source (journal and Dove Medical Press) must be acknowledged as original place of publication
    • Publisher's version/PDF may be used
    • All titles are open access journals
    • Publisher last contacted on 20/01/2013
  • Classification
    ​ blue

Publications in this journal

  • International Journal of COPD 01/2015;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Sleep problems are common in patients with Chronic Obstructive Pulmonary Disease (COPD) but the validity of Patient Reported Outcome Measures (PROMs) that measure sleep dysfunction has not been evaluated. We have reviewed the literature to identify disease-specific and non-disease specific sleep PROMs that have been validated for use on COPD patients. The review also examined the psychometric properties of identified sleep outcome measures and extracted point and variability estimates of sleep instruments used in COPD studies. Methods: The online databases EMBASE, MEDLINE, PsycINFO and SCOPUS for all years to May 2014 were used to source articles for the review. The review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Criteria from the Medical Outcomes Trust Scientific Advisory Committee guidelines were used to evaluate the psychometric properties of all identified sleep PROMs. Results: One COPD-specific and six non-COPD specific sleep outcome measures were identified and 44 papers met the review selection criteria. We only identified one instrument, the COPD and Asthma Sleep Impact Scale that has been developed specifically for use in COPD populations. 90% of identified studies used one of two non-disease specific sleep scales; The Pittsburgh Sleep Quality Index and/or the Epworth Sleep Scale, although neither has been tested for reliability or validity on people with COPD. Conclusions: The results highlight the need for existing non-disease specific instruments to be validated in COPD populations and also the need for new disease-specific measures to assess the impact of sleep problems in COPD.
    International Journal of COPD 01/2014; 10.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Exercise intolerance, exertional dyspnea, reduced health-related quality of life, and acute exacerbations are features characteristic of chronic obstructive pulmonary disease (COPD). Patients with a primary diagnosis of COPD often report comorbidities and other secondary manifestations, which diversifies the clinical presentation. Pulmonary rehabilitation that includes whole body exercise training is a critical part of management, and core programs involve endurance and resistance training for the upper and lower limbs. Improvement in maximal and submaximal exercise capacity, dyspnea, fatigue, health-related quality of life, and psychological symptoms are outcomes associated with exercise training in pulmonary rehabilitation, irrespective of the clinical state in which it is commenced. There may be benefits for the health care system as well as the individual patient, with fewer exacerbations and subsequent hospitalization reported with exercise training. The varying clinical profile of COPD may direct the need for modification to traditional training strategies for some patients. Interval training, one-legged cycling (partitioning) and non-linear periodized training appear to be equally or more effective than continuous training. Inspiratory muscle training may have a role as an adjunct to whole body training in selected patients. The benefits of balance training are also emerging. Strategies to ensure that health enhancing behaviors are adopted and maintained are essential. These may include training for an extended duration, alternative environments to undertake the initial program, maintenance programs following initial exercise training, program repetition, and incorporation of approaches to address behavioral change. This may be complemented by methods designed to maximize uptake and completion of a pulmonary rehabilitation program.
    International Journal of COPD 01/2014; in press.
  • International Journal of COPD 08/2013; 8:251-253.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Long-term oxygen therapy (LTOT) is the treatment proven to improve survival in chronic obstructive pulmonary disease (COPD) patients with chronic respiratory failure. It also appears to reduce the number of hospitalizations, increase effort capacity, and improve health-related quality of life. Standard LTOT criteria are related to COPD patients who have PaO2 < 60 mmHg, are in a clinical stable situation, and are receiving optimal pharmacological treatment. According to LTOT guidelines, oxygen should be prescribed for at least 18 hours per day although some authors consider 24 hours would be more beneficial. The benefits of LTOT depend on correction of hypoxemia. Arterial blood gases should be measured at rest. During exercise, an effort test should be done to assure adequate SaO2. During sleep, continuous monitoring of SaO2 and PaCO2 should be performed to confirm correction of SaO2 overnight. An arterial blood gas sample should be taken at awakening to assess PaCO, in order to prevent hypoventilation from the oxygen therapy. Several issues that need to be addressed are the use of LTOT in COPD patients with moderate hypoxemia, the efficacy of LTOT in patients who desaturate during exercise or during sleep, the optimal dosage of oxygen supplementation, LTOT compliance, and the LTOT prescription in diseases other than COPD.
    International Journal of COPD 06/2008; 3(2):231-7.
    This article is viewable in ResearchGate's enriched format